Serum-soluble TRAIL levels in patients with severe persistent allergic asthma: Its relation to omalizumab treatment


Creative Commons License

Yalcin A. D. , Bisgin A., Kargi A., Gorczynski R. M.

MEDICAL SCIENCE MONITOR, cilt.18, 2012 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 18 Konu: 3
  • Basım Tarihi: 2012
  • Doi Numarası: 10.12659/msm.882504
  • Dergi Adı: MEDICAL SCIENCE MONITOR

Özet

Background: In this study we compare the Omalizumab treatment modality in the dynamics of cell apoptosis regulating molecules in both severe persistent asthma patients who had no other any allergic disease, newly diagnosed patients with allergic asthma, and healthy volunteers.